NASDAQ:ACAD

Acadia Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy ACAD

*Your capital is at risk

$21.43

+0.540 (+2.58%)

At Close: Jun 03, 2026

ACADIA Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 4.71. In total, the insiders bought 1.41M and sold 147.72K ACAD shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	4.71
● Buy	1.41M shares
● Sell	147.72K shares
76% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence Mar 25, 2026 Analysis Breakdown: Weakened by a contradictory positive Insider Power Score. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 03, 2026 Buy	Common Stock J-Other	Poole Jonathan Insider	Other	0 Value: $0
Mar 03, 2026 Buy	Restricted Stock Units A-Award	Poole Jonathan Director	Director	2 010 Value: $45.2K
Mar 03, 2026 Buy	Director Stock Options (Right to Buy) A-Award	Poole Jonathan Director	Director	3 565 Value: $80.2K
Mar 03, 2026 Buy	Restricted Stock Units A-Award	Poole Jonathan Director	Director	4 218 Value: $94.9K
Mar 03, 2026 Buy	Director Stock Options (Right to Buy) A-Award	Poole Jonathan Director	Director	7 482 Value: $168.3K
Feb 09, 2026 Sell	Common Stock S-Sale	Rhodes Jennifer J EVP, Chief Legal Officer, Sec	Officer	6 950 Value: $162.5K
Feb 06, 2026 Buy	Common Stock M-Exempt	Rhodes Jennifer J EVP, Chief Legal Officer, Sec	Officer	12 944 Value: $305.0K
Feb 06, 2026 Buy	Restricted Stock Units M-Exempt	Rhodes Jennifer J EVP, Chief Legal Officer, Sec	Officer	12 944 Value: $305.0K
Nov 18, 2025 Sell	Common Stock S-Sale	Schneyer Mark C. EVP, Chief Financial Officer	C-Suite Officer	10 262 Value: $243.1K
Nov 18, 2025 Sell	Common Stock S-Sale	Kihara James Principal Accounting Officer	Officer	4 084 Value: $96.8K
Nov 17, 2025 Buy	Common Stock M-Exempt	Kihara James Principal Accounting Officer	Officer	3 966 Value: $95.2K
Nov 17, 2025 Buy	Common Stock M-Exempt	Kihara James Principal Accounting Officer	Officer	3 966 Value: $95.2K
Nov 17, 2025 Buy	Restricted Stock Units M-Exempt	Schneyer Mark C. EVP, Chief Financial Officer	C-Suite Officer	9 913 Value: $238.0K
Nov 17, 2025 Buy	Common Stock M-Exempt	Schneyer Mark C. EVP, Chief Financial Officer	C-Suite Officer	9 913 Value: $238.0K
Nov 17, 2025 Buy	Common Stock M-Exempt	Schneyer Mark C. EVP, Chief Financial Officer	C-Suite Officer	9 913 Value: $238.0K
Nov 17, 2025 Buy	Restricted Stock Units M-Exempt	Kihara James Principal Accounting Officer	Officer	3 966 Value: $95.2K
Nov 10, 2025 Sell	Common Stock S-Sale	Daly James M Director	Director	30 000 Value: $671.0K
Sep 15, 2025 Sell	Common Stock S-Sale	Schneyer Mark C. EVP, Chief Financial Officer	C-Suite Officer	3 498 Value: $82.7K
Sep 15, 2025 Sell	Common Stock S-Sale	Schneyer Mark C. EVP, Chief Financial Officer	C-Suite Officer	3 498 Value: $82.7K
Sep 12, 2025 Buy	Common Stock A-Award	Schneyer Mark C. EVP, Chief Financial Officer	C-Suite Officer	6 815 Value: $160.9K
Sep 12, 2025 Buy	Common Stock A-Award	Schneyer Mark C. EVP, Chief Financial Officer	C-Suite Officer	6 815 Value: $160.9K
Sep 02, 2025 Sell	Common Stock S-Sale	Garofalo Elizabeth A. Director	Director	1 600 Value: $41.6K
Sep 02, 2025 Sell	Common Stock S-Sale	Garofalo Elizabeth A. Director	Director	1 600 Value: $41.6K
Aug 18, 2025 Sell	Common Stock S-Sale	Schneyer Mark C. EVP, Chief Financial Officer	C-Suite Officer	22 000 Value: $554.0K
Aug 18, 2025 Sell	Common Stock S-Sale	Schneyer Mark C. EVP, Chief Financial Officer	C-Suite Officer	22 000 Value: $554.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ACADIA PHARMACEUTICALS INC.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psych...

Read Full Profile Here